Abstract: PROBLEMS TO BE SOLVED BY THE INVENTION To provide aqueous solutions of conophylline and/or conophyllidine; methods for purifying conophylline and/or conophyllidine from the aqueous solutions; methods for producing the aqueous solutions, water-soluble compositions containing conophylline and/or a conophyllidine useful for food compositions or pharmaceutical compositions or methods for preparing the same; as well as food compositions or pharmaceutical compositions containing the water-soluble compositions. MEANS OF SOLVING THE PROBLEMS It has been found that conophylline and/or conophyllidine can be efficiently extracted from a plant producing conophylline and/or conophyllidine with an acidic aqueous solution having a pH equal to or less than 4. The extract thus obtained, i.e., aqueous solution of conophylline, and/or conophyllidine is useful for production of, for instance, food compositions, pharmaceutical compositions, etc.
Abstract: The invention relates to surface modifying macromolecules (SMMs) having high degradation temperatures and their use in the manufacture of articles made from base polymers which require high temperature processing. The surface modifier is admixed with the base polymer to impart alcohol and water repellency properties.
Type:
Grant
Filed:
July 19, 2011
Date of Patent:
May 15, 2012
Assignee:
Interface Biologics Inc.
Inventors:
Sanjoy Mullick, Richard Witmeyer, Paul Santerre, Weilun Chang
Abstract: The present invention is directed to providing the IP-10 protein (interferon-?-inducible protein 10) as a novel therapeutic target relating to the etiology of bone diseases with bone destruction associated with RNAKL expression and osteoclast formation. More specifically, the present invention relates to (i) a pharmaceutical composition for preventing or treating a disease or disorder associated with the expression of RANKL (receptor activator of NF-?B ligand), (ii) a method for inhibiting the expression of RANKL and (iii) a method for screening an antibody drug candidate to inhibit the expression of RANKL.
Type:
Grant
Filed:
August 17, 2007
Date of Patent:
May 15, 2012
Assignee:
Seoul National University Industry Foundation
Inventors:
Young Wook Song, Zang Hee Lee, Eun Bong Lee, Eun Young Lee
Abstract: The present invention relates to hyaluronic acid ester derivatives, whose carboxylic groups are partially esterified with hydroxy groups of propiophenone derivatives, to the hydrogel materials consisting of the said hyaluronic acid ester derivatives, to their preparation process by photocuring of the hyaluronic acid ester derivatives, and their use in the biomedical, sanitary and surgical fields, and in the medical field as controlled release systems for drugs.
Abstract: By present invention it has been found that hypothermia decreases adhesion formation more specifically pneumoperitoneum-enhanced adhesion formation. A cooling system has been designed to reduce the peritoneal cavity temperature during surgery, while maintaining at all times a 100% relative humidity in order to prevent desiccation, and a regulatory unit designed to condition the insufflated gas to achieve this while minimalising the necessary cooling. This is a new method for more effectively preventing adhesion though cooling while preventing desiccation. In mice it was demonstrated that factors such as environmental temperature, anaesthesia, ventilation and pneumoperitoneum can be used to influence body temperature in order to prevent adhesion formation.
Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type, for example, insulin producing cells of the pancreas, blood cells, spleen cells, brain cells, heart cells, vascular tissue cells, cells of the bile duct, or skin cells, in a mammal (e.g., a human patient) that has injured or damaged cells of the predetermined type.
Abstract: The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.
Type:
Grant
Filed:
March 24, 2008
Date of Patent:
May 8, 2012
Assignee:
NeurAxon, Inc.
Inventors:
Shawn Maddaford, Jailall Ramnauth, Suman Rakhit, Joanne Patman, Subhash C. Annedi, John Andrews, Peter Dove, Sarah Silverman, Paul Renton
Abstract: In general, the invention relates to marrow-derived adult progenitor cells (MAPCs) and their use in methods of treating various medical disorders, typically caused by or involving loss of cells or loss of cell function. These cells, when administered, e.g., intranasally, can cross the blood brain barrier and terminally differentiate into cholinergic neurons or otherwise localize and terminally differentiate.
Type:
Grant
Filed:
August 8, 2007
Date of Patent:
May 1, 2012
Assignee:
McLean Hospital Corporation
Inventors:
Anne Cataldo, Chun-Wei Chen, Bruce M. Cohen
Abstract: The invention features methods diagnostic of a psychotic disorder such as bipolar disorder or schizophrenia. The methods include obtaining a cell sample from a subject, subjecting a cell from the sample to stress (e.g., nutrient stress), and measuring nucleic acid or polypeptide expression in the cell, where an alteration in expression is indicative of the subject having or being at increased risk of developing a psychotic disorder. The invention also features prognostic monitoring methods for subjects having a psychotic disorder, useful in determining the progression of a psychotic disorder in a subject or the effectiveness of a therapy.
Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.
Type:
Grant
Filed:
December 21, 2009
Date of Patent:
April 24, 2012
Assignee:
Zealand Pharma A/S
Inventors:
Bjarne Due Larsen, Yvette Miata Petersen
Abstract: The invention features methods for the identification of leucine-rich kinase 2 (LRRK2) inhibitors using indol ligand 91. Generally, these methods include identifying compounds that compete with indol ligand 91 for binding to LRRK2.
Abstract: An aqueous composition comprising a denaturing agent, a chelator, a buffering agent and a protease for the extraction of nucleic acid from a sample of bodily fluid, such as saliva, such that the extracted nucleic acid is stable for at least fourteen days at room temperature and can be directly utilized in an amplification reaction without further processing. In particular, said composition comprises SDS, Cyclohexanediamine tetraacetate, Tris-HCl and proteinase K. A method and kit for the amplification of DNA directly from a bodily fluid, comprising said composition, is further provided.
Type:
Grant
Filed:
March 14, 2006
Date of Patent:
April 17, 2012
Assignee:
DNA Genotek Inc.
Inventors:
Chaim H. Birnboim, Adele Jackson, Rafal Iwasiow, Joanne Chartier, Paul Lem
Abstract: The present invention provides 5-azacytosine derivatives with antiviral activity, specifically having viral replication inhibiting properties, more particularly in DNA viruses such as pox-, papilloma- and herpes viruses in humans. The invention also provides pharmaceutical compositions comprising such 5-azacytosine derivatives as active ingredients in combination with pharmaceutically acceptable carriers, which are useful for the treatment of subjects suffering from viral infections.
Type:
Grant
Filed:
December 8, 2006
Date of Patent:
April 10, 2012
Assignees:
K.U. Leuven Research & Development, Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic
Inventors:
Antonin Holy, Marcela Krecmerova, Alois Piskala, Graciela Andrei, Robert Snoeck, Erik De Clercq, Johan Neyts, Lieve Naesens
Abstract: The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer, and intermediates for the synthesis of such compositions.
Type:
Grant
Filed:
August 12, 2010
Date of Patent:
April 3, 2012
Assignee:
Eisai R&D Management Co., Ltd.
Inventors:
Boris M. Seletsky, Melvin J. Yu, Wanjun Zheng
Abstract: Porous calcium phosphate implant compositions that approximate the chemical composition of natural bone mineral are provided. In addition to calcium phosphate, the compositions include an effervescent agent to promote the formation of interconnected pores and a cohesiveness agent to maintain the shape and hardness of the hardened composition. When introduced at an implant site, the calcium phosphate compositions are remodeled into bone. Methods for using the calcium phosphate compositions, e.g., to repair or replace bone, are also provided.
Type:
Grant
Filed:
December 6, 2005
Date of Patent:
April 3, 2012
Assignee:
ETEX Corporation
Inventors:
Aron D. Rosenberg, Laurent D. Gillès de Pélichy, Shrikar Bondre, Michael Strunk
Abstract: The present invention relates to stabilizers for compositions, including immunogenic compositions, such as vaccine compositions, comprising one or more live attenuated flaviviruses, to bulk vaccine compositions stabilized with these stabilizers, particularly dry vaccine compositions prepared from these bulk vaccine compositions, and to methods for stabilizing one or more live attenuated flaviviruses.
Type:
Grant
Filed:
July 9, 2009
Date of Patent:
March 27, 2012
Assignee:
Sanofi Pasteur
Inventors:
Alain Françon, Olivier Brass, Pierre Chouvenc, Amandine Leleu
Abstract: The present invention is related to novel parathyroid hormone polypeptide derivatives, and to pharmaceutical composition containing the polypeptides, as well as synthetic and recombinant methods for producing the polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing the polypeptides of the present invention. The present invention further provides diagnostic and therapeutic methods using the polypeptide derivatives.
Type:
Grant
Filed:
August 3, 2007
Date of Patent:
March 27, 2012
Assignee:
The General Hospital Corporation
Inventors:
Henry M. Kronenberg, John T. Potts, Jr., Thomas J. Gardella